



DEFENSE
HEALTH AGENCY

MB&RS

**OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
HEALTH AFFAIRS
16401 EAST CENTRETECH PARKWAY
AURORA, CO 80011-9066**

**CHANGE 157
6010.57-M
FEBRUARY 16, 2016**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL
FOR
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The Defense Health Agency has authorized the following addition(s)/revision(s).

CHANGE TITLE: EVOLVING PRACTICES 16-001

CONREQ: 17830

PAGE CHANGE(S): See page 2.

SUMMARY OF CHANGE(S): See page 3.

EFFECTIVE DATE: See page 3.

IMPLEMENTATION DATE: March 16, 2016.

**GREEN.ELAN
.PARKER.138
6505752**
Digitally signed by
GREEN.ELAN.PARKER.1386505752
DN: c=US, o=U.S. Government,
ou=DoD, ou=PKI, ou=DHA,
cn=GREEN.ELAN.PARKER.1386505
752
Date: 2016.02.11 15:38:58 -0700

**Ann N. Fazzini
Team Chief, Medical Benefits &
Reimbursement Section (MB&RS)
Defense Health Agency (DHA)**

**ATTACHMENT(S): 25 PAGE(S)
DISTRIBUTION: 6010.57-M**

WHEN PRESCRIBED ACTION HAS BEEN TAKEN, FILE THIS TRANSMITTAL WITH BASIC DOCUMENT.

CHANGE 157
6010.57-M
FEBRUARY 16, 2016

REMOVE PAGE(S)

CHAPTER 1

Section 3.1, page 3

CHAPTER 4

Section 6.1, pages 1 - 4

Section 21.1, pages 1 and 2

Section 24.1, pages 3 - 6

Section 24.2, pages 3 - 5

Section 24.3, pages 1, 2, 5

CHAPTER 5

Section 3.1, pages 1 - 5

CHAPTER 6

Section 1.1, pages 1-3

INSERT PAGE(S)

Section 3.1, page 3

Section 6.1, pages 1 - 4

Section 21.1, pages 1 and 2

Section 24.1, pages 3 - 6

Section 24.2, pages 3 - 5

Section 24.3, pages 1, 2, 5

Section 3.1, pages 1 - 5

Section 1.1, pages 1 - 3

SUMMARY OF CHANGES

CHAPTER 1

1. Section 3.1. This change establishes Photodynamic Therapy with off-label use of Visudyne for the treatment of Central Serous Chorioretinopathy. EFFECTIVE DATE: 12/01/2014.

CHAPTER 4

2. Section 6.1. This change establishes Meniscal Allograft Transplant of the Knee treatment. EFFECTIVE DATE: 05/01/2015.
3. Section 21.1. This change establishes Photodynamic Therapy with off-label use of Visudyne for the treatment of Central Serous Chorioretinopathy. EFFECTIVE DATE: 12/01/2014.
4. Section 24.1. This change establishes AlloMap® Molecular Expression Testing for Cardiac Transplant Rejection Surveillance. EFFECTIVE DATE: 02/19/2015.
5. Section 24.2. This change establishes AlloMap® Molecular Expression Testing for Cardiac Transplant Rejection Surveillance. EFFECTIVE DATE: 02/19/2015.
6. Section 24.3. This change establishes AlloMap® Molecular Expression Testing for Cardiac Transplant Rejection Surveillance. EFFECTIVE DATE: 02/19/2015.

CHAPTER 5

7. Section 3.1. This change establishes Selective Internal Radiation Therapy with Yttrium-90 Microspheres for the Treatment of Unresectable Liver Tumors from Metastatic Breast Cancer. EFFECTIVE DATE: 07/04/2014.

CHAPTER 6

8. Section 1.1. This change establishes AlloMap® Molecular Expression Testing for Cardiac Transplant Rejection Surveillance. EFFECTIVE DATE: 02/19/2015.

